TP53 and non-small cell lung carcinoma: One multiple-cohort study included patients with NSCLC from the Gene plus Institute, the Cancer Genome Atlas (TCGA), and the Memorial Sloan Kettering Cancer Center (MSKCC) databases and from the POPLAR and OAK randomized controlled trials and found that TP53 and ataxia-telangiectasia mutated (ATM) co-mutation was associated with a significantly higher TMB compared with the sole mutation and with no mutation.